Does ALIROCUMAB Cause Nephrolithiasis? 42 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 42 reports of Nephrolithiasis have been filed in association with ALIROCUMAB (Praluent). This represents 0.2% of all adverse event reports for ALIROCUMAB.
42
Reports of Nephrolithiasis with ALIROCUMAB
0.2%
of all ALIROCUMAB reports
1
Deaths
23
Hospitalizations
How Dangerous Is Nephrolithiasis From ALIROCUMAB?
Of the 42 reports, 1 (2.4%) resulted in death, 23 (54.8%) required hospitalization, and 1 (2.4%) were considered life-threatening.
Is Nephrolithiasis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ALIROCUMAB. However, 42 reports have been filed with the FAERS database.
What Other Side Effects Does ALIROCUMAB Cause?
Myalgia (1,571)
Product dose omission (1,354)
Injection site pain (1,220)
Muscle spasms (1,113)
Arthralgia (993)
Fatigue (922)
Pain (892)
Pain in extremity (888)
Product dose omission issue (864)
Injection site bruising (821)
What Other Drugs Cause Nephrolithiasis?
ADALIMUMAB (2,416)
ETANERCEPT (1,292)
INFLIXIMAB (981)
METHOTREXATE (979)
ABATACEPT (788)
TOPIRAMATE (768)
CERTOLIZUMAB PEGOL (735)
RITUXIMAB (709)
TOFACITINIB (699)
SODIUM OXYBATE (698)
Which ALIROCUMAB Alternatives Have Lower Nephrolithiasis Risk?
ALIROCUMAB vs ALISKIREN
ALIROCUMAB vs ALISKIREN HEMIFUMARATE
ALIROCUMAB vs ALISKIREN\HYDROCHLOROTHIAZIDE
ALIROCUMAB vs ALIZAPRIDE
ALIROCUMAB vs ALLANTOIN